Results 241 to 250 of about 68,369 (257)

Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales

Clinical Infectious Diseases, 2022
Abstract Piperacillin-tazobactam (PTZ) is one of the most common antibiotics administered to hospitalized patients. Its broad activity against gram-negative, gram-positive, and anaerobic pathogens; efficacy in clinical trials across diverse infection types and patient populations; and generally favorable toxicity profile make it a ...
Pranita D Tamma, Patrick N A Harris, Amy J Mathers, Eric Wenzler, Romney M Humphries   +4 more
openaire   +2 more sources

Carbapenem susceptibility breakpoints, clinical implications with the moving target

Expert Review of Anti-infective Therapy, 2016
Carbapenems are primary agents used to treat a variety of Gram-negative multi-drug resistant infections. In parallel with increasing use, increasing resistance to carbapenem agents has manifested as increased minimum inhibitory concentrations (MICs). To attempt to improve clinical outcomes with carbapenems, the Clinical Laboratory Standards Institute ...
J Nicholas, O'Donnell, Cristina M, Miglis, Jane Y, Lee, Merika, Tuvell, Tina, Lertharakul, Marc H, Scheetz   +5 more
openaire   +2 more sources

Prevalence, breakpoint distribution, and clinical correlates of t(5;12)

Cancer Genetics and Cytogenetics, 2004
Among 56,709 cytogenetic studies performed during a 15-year period at the Mayo Clinic, 25 cases of t(5;12) were identified. Among 11 patients with available clinical information, 4 had myelodysplastic syndrome, 2 had acute myelocytic leukemia, 2 had myelofibrosis with myeloid metaplasia (MMM), 2 had atypical chronic myelocytic disorder (ACMD), and 1 ...
Patricia T, Greipp, Gordon W, Dewald, Ayalew, Tefferi   +2 more
openaire   +2 more sources

Comparison of antimicrobial pharmacokinetic/pharmacodynamic breakpoints with EUCAST and CLSI clinical breakpoints for Gram-positive bacteria

International Journal of Antimicrobial Agents, 2012
This study compared the susceptibility breakpoints based on pharmacokinetic/pharmacodynamic (PK/PD) models and Monte Carlo simulation with those defined by the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) for antibiotics used for the treatment of infections caused by Gram-
Eduardo, Asín, Arantxazu, Isla, Andrés, Canut, Alicia, Rodríguez Gascón   +3 more
openaire   +2 more sources

A Long Journey from Minimum Inhibitory Concentration Testing to Clinically Predictive Breakpoints: Deterministic and Probabilistic Approaches in Deriving Breakpoints

Infection, 2009
Since the origin of an "'International Collaborative Study on Antibiotic Sensitivity Testing'" in 1971, considerable advancement has been made to standardize clinical susceptibility testing procedures of antimicrobial agents. However, a consensus on the methods to be used and interpretive criteria was not reached, so the results of susceptibility ...
A, Dalhoff, P G, Ambrose, J W, Mouton
openaire   +2 more sources

Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia

International Journal of Antimicrobial Agents, 2021
The application of cefepime breakpoint for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteraemia has not been explored. Adult cases of monomicrobial bloodstream infection (BSI) caused by cefepime-susceptible [minimum inhibitory concentration (MIC) ≤8 mg/L] K.
Nan-Yao Lee, Ching-Lung Lo, Po-Lin Chen, Ling-Shan Syue, Chia-Wen Li, Ming-Chi Li, Wen-Chien Ko   +6 more
openaire   +2 more sources

Breakpoints in Antibiotic Sensitivity Testing and Their Clinical Relevance

Journal of Chemotherapy, 1997
Antibiotic sensitivity testing has been developed into a highly sophisticated process technically. Interpretation of results obtained requires the definition of breakpoints in order to separate sensitive (likely to respond to treatment) from resistant (likely to persist despite treatment) strains. Various methods used for the setting of breakpoints are
openaire   +3 more sources

Antimicrobial susceptibility of 6 antimicrobial agents in Helicobacter pylori clinical isolates by using EUCAST breakpoints compared with previously used breakpoints

Enfermedades Infecciosas y Microbiología Clínica, 2017
The aim of this study was to determine the differences in percentage resistance in H. pylori clinical isolates using EUCAST breakpoints compared with previously used breakpoints. MIC value distribution in H. pylori clinical isolates was also studied.Susceptibility to amoxicillin, tetracycline, metronidazole, clarithromycin, rifampicin and levofloxacin ...
Teresa, Alarcón, Pedro, Urruzuno, Maria Josefa, Martínez, Diego, Domingo, Laura, Llorca, Ana, Correa, Manuel, López-Brea   +6 more
openaire   +2 more sources

Can We Achieve Clinical Breakpoints for the Triazoles in Aspergillosis?

Current Fungal Infection Reports, 2011
The azoles are first-line agents for the treatment of aspergillosis. A number of recent studies have shown increasing rates of resistance in A. fumigatus. Consequently, reliable in vitro susceptibility testing and breakpoints that appropriately classify resistant isolates are of paramount importance.
Juan Luis Rodriguez-Tudela, William Hope, Manuel Cuenca-Estrella, J. Peter Donnelly, Cornelia Lass-Flörl, Maiken C. Arendrup   +5 more
openaire   +1 more source

MIC and clinical efficacy. From systemic to ocular breakpoints

Acta Ophthalmologica, 2008
AbstractAbstract not ...
openaire   +1 more source